Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects

Phase 1 Completed 42 enrolled AstraZeneca Bristol-Myers Squibb · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

To assess the potential pharmacokinetic (PK) interactions of bumetanide and dapagliflozin following multiple doses of 1 mg bumetanide and 10 mg dapagliflozin in healthy subjects

Timeline

Start: 2009-07
Primary completion: 2009-09
Completion: 2009-09

Publications

Wilcox CS, Shen W, Boulton DW, Leslie BR, Griffen SC. Interaction Between the Sodium-Glucose-Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diuretic Bumetanide in Normal Human Subjects. J Am Heart Assoc. 2018 Feb 10;7(4):e007046. doi: 10.1161/JAHA.117.007046.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Bumetanide	Small molecule	1 mg	Oral
Comparator	Dapagliflozin	Small molecule	10 mg	Oral

Study to Evaluate the Potential Pharmacokinetic Interaction and Pharmacodynamic Effects on Renal Parameters of Bumetanide (1mg) and Dapagliflozin (10 mg) When Co-administered in Healthy Subjects

Summary

Timeline

Publications

Drugs

Indications